| P50 | author | Shivaprakash Rudramurthy | Q43247718 |
| | Arunaloke Chakrabarti | Q45924527 |
| | Jacques F. Meis | Q51269909 |
| | Manpreet Dhaliwal | Q114425552 |
| | Seyedmojtaba Seyedmousavi | Q40062294 |
| | Johan Mouton | Q42711138 |
| P2860 | cites work | In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. | Q42726676 |
| | Azole-resistant Aspergillus fumigatus, Iran. | Q43171569 |
| | Azole resistance in Aspergillus: a growing public health menace | Q43607400 |
| | Azole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India | Q43895542 |
| | An opportunistic human pathogen on the fly: strains of Aspergillus flavus vary in virulence in Drosophila melanogaster | Q44622508 |
| | EUCAST technical note on voriconazole and Aspergillus spp. | Q45886335 |
| | In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs. | Q51037587 |
| | Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. | Q54342323 |
| | Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis | Q56993324 |
| | Invasive aspergillosis in critically ill patients without malignancy | Q80269940 |
| | Azole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles? | Q28082352 |
| | Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 |
| | Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America | Q28263689 |
| | Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis | Q34290034 |
| | Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice | Q35168955 |
| | Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model | Q35385554 |
| | The T788G mutation in the cyp51C gene confers voriconazole resistance in Aspergillus flavus causing aspergillosis | Q35941367 |
| | Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis. | Q36505281 |
| | Pharmacokinetic/pharmacodynamic profile of voriconazole | Q36520587 |
| | Pharmacokinetics and pharmacodynamics of antifungals | Q36598067 |
| | Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis | Q36757621 |
| | Aspergillus flavus: human pathogen, allergen and mycotoxin producer. | Q36831943 |
| | Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus | Q37226618 |
| | Aspergillus flavus: an emerging non-fumigatus Aspergillus species of significance | Q37389864 |
| | The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside. | Q38234496 |
| | Therapeutic outcome in invasive aspergillosis | Q38970340 |
| | In vitro antifungal susceptibility of clinically relevant species belonging to Aspergillus section Flavi. | Q39767031 |
| | A Novel Y319H Substitution in CYP51C Associated with Azole Resistance in Aspergillus flavus. | Q40653596 |
| | Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles | Q42018512 |
| | Comparative Evaluation of Disc Diffusion and E-test with Broth Micro-dilution in Susceptibility testing of Amphotericin B, Voriconazole and Caspofungin against Clinical Aspergillus isolates | Q42191165 |
| | Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania. | Q42206937 |
| | Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document) | Q42428186 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Aspergillus flavus | Q137096 |
| | aspergillosis | Q259626 |
| | voriconazole | Q412236 |
| | pharmacodynamics | Q725307 |
| | murine model | Q122890741 |
| P577 | publication date | 2016-11-07 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis | |
| P478 | volume | 61 | |